Blog›Cost
Cost·15 min read·Published Jun 28, 2026·Updated Oct 20, 2026

How Much Is Wegovy Without Insurance? (2026 Cost)

How much is Wegovy without insurance in 2026? List ~$1,349/mo; NovoCare self-pay ~$349 or ~$149 for the pill. Full cost breakdown, savings options

Nouri Editorial Team

Medically reviewed by Amber Patel, MD · Jun 28, 2026

Quick answer: Wegovy® (semaglutide injection, by Novo Nordisk) is the FDA-approved medication for chronic weight management. Without insurance, its list price is about $1,349/month — but Novo’s NovoCare self-pay program sells the injectable pen for $349/month at every dose from 0.25 to 2.4 mg (new patients pay $199 for each of their first two fills of the 0.25 and 0.5 mg pens, through Dec 31, 2026), and the Wegovy pill starts at $149/month. With commercial insurance that covers it, a savings card can bring the copay to as little as $25/month — but roughly 40% of employer plans exclude weight-loss drugs. There is no generic Wegovy; patents extend to approximately 2032.

Key takeaways
  • Wegovy’s list price is ~$1,349/mo, but almost nobody pays it — NovoCare self-pay is $349 (pen, 0.25–2.4 mg), $399 (Wegovy HD 7.2 mg) or $149–$299 (pill, by dose).
  • With commercial insurance that covers Wegovy, a savings card can bring the copay to as little as $25/month; ~40% of employer plans exclude weight-loss drugs.
  • No generic Wegovy exists (Novo Nordisk patents to ~2032). Compounded semaglutide is a patient-specific, non-FDA-approved option available via licensed prescribers.
  • Prices checked Oct 13, 2026 on NovoCare. The $199 intro offer ends Dec 31, 2026; verify current figures and your insurer’s formulary before you fill.

Compare semaglutide prices →

Wegovy cost without insurance: at a glance

Way to get Wegovy or semaglutideCost / month (checked Oct 13, 2026)Notes
Wegovy injectable pen (list price)~$1,349Sticker price; few people pay this. Novo has announced a $675 list price from Jan 1, 2027
Wegovy pen (NovoCare self-pay)$349 ($199 intro)$349 at every dose from 0.25 to 2.4 mg. New patients pay $199 for each of their first 2 fills of the 0.25 and 0.5 mg pens, through Dec 31, 2026
Wegovy HD 7.2 mg pen (NovoCare self-pay)$399Only after at least 4 weeks on 2.4 mg
Wegovy pill / oral semaglutide (self-pay)$149–$299$149 at 1.5 mg, $199 at 4 mg, $299 at 9 and 25 mg. FDA-approved December 2025; daily pill, empty stomach required
Wegovy with commercial insurance + savings cardAs low as $25Requires plan coverage; most plans need prior authorization
Compounded semaglutide (telehealth providers we compared)~$99–$299All-in at the starting dose, Oct 2026 (our comparison). Not FDA-approved; not the same as Wegovy

Brand prices checked Oct 13, 2026 on NovoCare; savings and intro offers end Dec 31, 2026, and prices change frequently. Verify all figures with the manufacturer, your pharmacy, and your insurer before deciding. For a broader comparison across all GLP-1 programs, see the complete 2026 GLP-1 cost guide.

What Wegovy actually costs without insurance

The ~$1,349 list price is the wholesale acquisition cost — a sticker number that most patients never pay. The figure that matters for self-pay patients is the NovoCare self-pay price: $349/month for the injectable pen at every dose from 0.25 to 2.4 mg, and $399 for the 7.2 mg Wegovy HD pen (checked Oct 13, 2026 on Novo Nordisk’s NovoCare page).

Novo also introduced an oral version — the Wegovy pill — which starts at a lower self-pay price of $149/month at 1.5 mg ($199 at 4 mg, $299 at 9 and 25 mg). If the daily-pill routine works for you, this is currently the lowest-cost FDA-approved semaglutide option at self-pay.

Why is the list price so high? Brand-name GLP-1 medications carry significant R&D and patent costs, and no biosimilar or generic has reached the U.S. market yet. Until competition arrives — analysts project semaglutide biosimilars in the late 2020s — the list price will remain largely a reference number for insurance negotiations. Novo Nordisk has announced a US list price of $675 a month for Wegovy, Ozempic and Rybelsus from Jan 1, 2027; it says the change does not affect self-pay prices.

Offer deadline: NovoCare’s $199 price covers a new patient’s first two monthly fills of the 0.25 mg and 0.5 mg Wegovy pens, through Dec 31, 2026; after that the pen is $349. Check the current terms on Wegovy.com’s savings page before you fill.

How NovoCare self-pay pricing works

NovoCare is Novo Nordisk’s patient-support program. At self-pay (meaning: you have no insurance, or your insurance does not cover Wegovy, or you choose not to use insurance), NovoCare sets the price directly with the patient rather than billing through a plan.

As of Oct 13, 2026, the self-pay injectable pen is $349/month at every dose from 0.25 to 2.4 mg, and the Wegovy HD 7.2 mg pen is $399. New patients pay $199/month for their first two fills of the 0.25 mg and 0.5 mg pens, through Dec 31, 2026; Novo says it may change or end the offer, so verify it before you begin treatment. To access NovoCare pricing, patients typically fill through a participating pharmacy and use the NovoCare program materials from their prescriber.

NovoCare self-pay pricing is not the same as an insurance savings card. Savings cards require an active commercial insurance plan that covers the drug; self-pay pricing is for patients paying out of pocket with no insurance billing.

The Wegovy pill: a lower-cost self-pay option

Every dose, with the savings card, Medicare and a first-year total, is on our Wegovy pill cost by dose page (NovoCare prices checked Oct 20, 2026).

In December 2025, the FDA approved an oral semaglutide tablet (25 mg) under the Wegovy brand for chronic weight management. At self-pay, it is $149/month at the 1.5 mg starting dose, $199 at 4 mg and $299 at 9 and 25 mg — less than the injectable pen’s $349 at every dose.

The trade-offs: the pill must be taken once daily on an empty stomach, with no food or drink for 30 minutes after taking it, and with a full glass of plain water only. Absorption can be significantly reduced by food, other beverages, or other medications taken at the same time. For people who prefer not to self-inject once weekly, the pill is a compelling alternative on cost; for people who find the administration requirements easy to miss, the once-weekly injection may be more reliable in practice.

Both the injectable pen and the pill are FDA-approved brand-name Wegovy products containing semaglutide, made by Novo Nordisk. Neither is a compounded product.

Wegovy cost with insurance

If your commercial insurance plan covers Wegovy, Novo Nordisk offers a savings card that can reduce your copay to as little as $25/month. That figure comes with important conditions: the drug must be on your plan’s formulary, your plan must not exclude weight-loss drugs, and you must not be on Medicare or Medicaid (savings cards do not apply to federal programs).

Coverage is the central obstacle. Studies of employer health plans have found that roughly 40% exclude weight-loss drugs entirely. Many that do cover them require prior authorization, documenting a BMI of 30 or higher (or 27+ with a weight-related comorbidity), and often require documentation that the patient has tried other weight-management strategies first. Getting that authorization approved can take weeks and may require your prescriber to submit supporting records.

Medicare coverage for Wegovy

Traditional Medicare Part D historically excluded weight-loss drugs under a statutory carve-out. Since July 1, 2026, the CMS Medicare GLP-1 Bridge lets eligible Part D members get Wegovy (pen, HD pen or pill) for $50/month with prior authorization, through Dec 31, 2027. Verify the current drug list and eligibility rules on the CMS newsroom page, as details may change.

Medicaid coverage for Wegovy

Medicaid coverage for GLP-1 weight-loss medications varies by state. As of mid-2026, a minority of state Medicaid programs cover Wegovy or similar medications for weight management — and where they do, requirements differ substantially. Check your state’s Medicaid formulary directly. Manufacturer savings cards (including Novo’s) do not apply to Medicaid.

Why Wegovy costs more than Ozempic — and when that matters

Wegovy and Ozempic are both brand-name semaglutide products made by Novo Nordisk, but they are different products with different FDA-approved indications and dosing schedules. Wegovy is FDA-approved for chronic weight management; Ozempic is FDA-approved for type 2 diabetes management and cardiovascular risk reduction.

The dosing is different: Wegovy goes up to 2.4 mg once weekly, while Ozempic’s approved doses top out at 1 mg or 2 mg weekly for diabetes. The list prices reflect this: Wegovy’s list is about $1,349/month, higher than Ozempic’s; Novo has announced a single $675 list price for both from Jan 1, 2027. At NovoCare self-pay, both pens cost $349/month (Ozempic up to 1 mg; $499 at 2 mg).

For a detailed breakdown of both products on cost and coverage, see the semaglutide cost guide, which covers Wegovy, Ozempic, and Rybelsus side by side.

Is there a generic version of Wegovy?

No. Novo Nordisk holds multiple patents on semaglutide — including the molecule, the injection device, and the formulation — that analysts project will not begin to expire until approximately 2032. No FDA-approved generic semaglutide product is available in the United States as of mid-2026.

The closest lower-cost alternative is compounded semaglutide — patient-specific preparations made by state-licensed 503A compounding pharmacies. These are not FDA-approved, not the same as Wegovy, and not therapeutically equivalent to any FDA-approved drug. Compounded semaglutide can only be obtained with a valid prescription from a licensed provider. See the dedicated section below for details on how compounding fits into the cost picture.

How Wegovy compares to Zepbound on cost

Zepbound (tirzepatide, by Eli Lilly) is the other major FDA-approved injectable for weight management. At self-pay, LillyDirect, Lilly’s online pharmacy, prices Zepbound vials and KwikPens at $299–$449/month, from $299 at the 2.5 mg starting dose up to $449 at the top doses when refills come on time (up to $699 when they don’t); LillyDirect doesn’t sell the single-dose pen self-pay (prices as of Oct 13, 2026). That puts it in a similar range to Wegovy’s $349/month NovoCare self-pay price; the comparison depends on which dose your prescriber recommends.

These are different drugs. Wegovy contains semaglutide (a GLP-1 receptor agonist); Zepbound contains tirzepatide (a dual GIP/GLP-1 receptor agonist). They work through related but distinct mechanisms and are not interchangeable. In published clinical trials of the FDA-approved branded drugs — STEP-1 for semaglutide (Wilding et al., NEJM 2021) and SURMOUNT-1 for tirzepatide (Jastreboff et al., NEJM 2022) — tirzepatide showed greater average weight loss than semaglutide. Individual results vary; these are trials of the branded drugs, not of any compounded product. Which medication is appropriate for a given patient is a clinical decision made by a licensed provider.

For a full cost-side breakdown of Zepbound at each tier, see Zepbound cost without insurance.

Compounded semaglutide: a non-FDA-approved lower-cost path

What it is. Compounded semaglutide is a patient-specific medication prepared by a state-licensed 503A compounding pharmacy. It is not manufactured by Novo Nordisk and is not FDA-approved. The FDA’s guidance on human drug compounding makes clear that compounded drugs do not undergo the same safety, efficacy, and manufacturing review as FDA-approved drugs. Compounded semaglutide is not the same as, and is not therapeutically equivalent to, Wegovy or any other FDA-approved semaglutide product.

How it is prescribed. A licensed provider evaluates the patient and, when clinically appropriate, issues a prescription. The prescription is filled by a state-licensed 503A pharmacy. Not every patient is a candidate; prescribers make that determination. The NIDDK overview of prescription weight-management medications provides context on how providers evaluate these options.

What it costs. Telehealth programs offering compounded semaglutide vary widely in their pricing and what is included. Market prices run roughly $99–$199/month, though what is bundled into that figure varies. Watch for “$99/month” teaser pricing that adds a separate $49–$79/month membership on top; compare all-in costs. Our GLP-1 price comparison ranks the providers we have reviewed by all-in price, with the date each was checked; the GLP-1 telehealth pricing dataset on HuggingFace is an older (June 2026) snapshot.

Regulatory context. The FDA has raised concerns about compounded GLP-1 products, including issues with labeling, dosing, and unauthorized versions of the drugs. Patients considering compounded semaglutide should use only licensed prescribers and state-licensed 503A compounding pharmacies, not grey-market or unapproved suppliers. See the FDA’s postmarket safety information page for current guidance.

How to compare Wegovy and other GLP-1 prices

Nouri does not prescribe, dispense or sell any medication; its former telehealth program has closed. It is an independent editorial site that compares licensed providers’ published prices, with the date each was checked.

The “$99/month” headline prices you see from some providers add a separate membership fee on top; compare the all-in number, not just the medication line item, when evaluating options.

Important: Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, Wegovy, Ozempic, Zepbound, or Mounjaro. A licensed prescriber decides whether any medication is clinically appropriate.

Compare published GLP-1 prices →

Related cost guides

Frequently asked questions

How much is Wegovy without insurance per month?

Wegovy’s list price is about $1,349/month, but Novo’s NovoCare self-pay pharmacy sells the pen for $349/month at every dose from 0.25 to 2.4 mg, and new patients pay $199 for each of their first two fills of the 0.25 and 0.5 mg pens through Dec 31, 2026. Wegovy HD 7.2 mg is $399/month, and the Wegovy pill is $149 at 1.5 mg, $199 at 4 mg and $299 at 9 and 25 mg (prices checked Oct 13, 2026).

Why is Wegovy more expensive than Ozempic?

Both are brand-name semaglutide products made by Novo Nordisk, but Wegovy is dosed higher for weight management (up to 2.4 mg weekly, or 7.2 mg for Wegovy HD) versus Ozempic for type 2 diabetes (up to 2 mg weekly), and Wegovy carries a higher list price (~$1,349/month). Novo has announced a single $675 list price for both from Jan 1, 2027. At NovoCare self-pay, both pens are $349/month (Ozempic up to 1 mg; $499 at 2 mg).

How much is Wegovy with insurance?

If your commercial plan covers Wegovy for weight management, a Novo savings card can bring the copay to as little as $25/month. However, roughly 40% of employer plans exclude weight-loss medications, most require prior authorization, and manufacturer savings cards do not apply to Medicare or Medicaid. Check your plan’s formulary before assuming coverage. For a full walkthrough, see does insurance cover Wegovy & Zepbound?

How do I get Wegovy for $199 a month?

NovoCare charges new patients $199 for each of their first two monthly fills of the 0.25 mg and 0.5 mg Wegovy pens, through Dec 31, 2026. After those two fills, and at higher doses, the self-pay pen is $349/month. Novo may change or end the offer, so check the current terms on Wegovy.com before you fill.

Is the Wegovy pill cheaper than the injection?

At self-pay, yes: the Wegovy pill (oral semaglutide, FDA-approved December 2025) is $149/month at 1.5 mg, $199 at 4 mg and $299 at 9 and 25 mg, versus $349 for the pen at every dose to 2.4 mg. The pill must be taken daily on an empty stomach with strict timing; the injection is taken once weekly.

Is Zepbound cheaper than Wegovy?

Self-pay prices overlap: LillyDirect charges $299 for Zepbound at the 2.5 mg starting dose, rising to $449 at the top doses when refills come on time, while NovoCare charges $349 for the Wegovy pen at every dose up to 2.4 mg (prices as of Oct 13, 2026). Zepbound contains tirzepatide and Wegovy contains semaglutide; they are different molecules and are not interchangeable. In published trials of the branded drugs, tirzepatide showed greater average weight loss than semaglutide; individual results vary.

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide is a patient-specific medication prepared by a state-licensed 503A compounding pharmacy. It is not FDA-approved and is not the same as, or therapeutically equivalent to, Wegovy or any other FDA-approved semaglutide product. It can only be obtained with a valid prescription from a licensed provider, who determines whether it is clinically appropriate for the individual patient. The FDA has issued guidance on compounded GLP-1 medications — see FDA.gov on human drug compounding for current information.

The bottom line

Without insurance, the real Wegovy self-pay price is $349/month for the pen ($199 for a new patient’s first two fills through Dec 31, 2026), $399 for Wegovy HD, or $149–$299/month for the pill — not the $1,349 list sticker. With covered commercial insurance, a savings card can bring that to ~$25/month. No generic exists. Compounded semaglutide — not FDA-approved and not the same as Wegovy — is available via licensed prescribers at lower monthly prices; compare programs on their all-in cost, not just the headline figure. See what licensed providers charge.

Semaglutide isn’t the only cash-pay GLP-1 route: tirzepatide with no insurance covers cash-pay routes to the other GLP-1 molecule.

Sources & references

  1. Wegovy.com — NovoCare self-pay and savings options (Novo Nordisk; checked Oct 13, 2026)
  2. NovoCare — Wegovy pen, HD and pill self-pay prices (Novo Nordisk; checked Oct 13, 2026)
  3. Novo Nordisk — US list price of Wegovy, Ozempic and Rybelsus to $675/month from Jan 1, 2027 (Feb 24, 2026)
  4. LillyDirect — Zepbound self-pay vials and KwikPen (Eli Lilly; checked Oct 13, 2026)
  5. CMS — Medicare GLP-1 Bridge Program ($50/month, July 2026); CMS Medicare GLP-1 Bridge page (through Dec 31, 2027)
  6. FDA — Human drug compounding overview
  7. FDA — Postmarket drug safety information (GLP-1 compounding concerns)
  8. NIDDK / NIH — Prescription medications to treat overweight and obesity
  9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM 2021.
  10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022.
  11. GoodRx — GLP-1 drug cost and savings overview
  12. Telehealth pricing — GLP-1 telehealth pricing dataset, HuggingFace (June 2026); joinnouri.com/weight-loss.

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as pricing and guidance change. Last reviewed June 2026.

Brand prices were checked Oct 13, 2026; coverage details date from June 2026. Both change frequently — verify current figures with the manufacturer, your pharmacy, your insurer, and (for HSA/FSA or tax questions) a tax professional before making decisions. This is general information, not medical, financial, or tax advice. Individual results vary. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Nouri is a publisher; it does not prescribe or sell any medication.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Nouri is an independent publisher: it does not prescribe, review patient assessments, or sell medication. Talk to a licensed clinician before starting or changing any medication or treatment.

Before you choose

Compare licensed GLP-1 providers

Published cash prices side by side, with the month we checked them and a link to each provider's own site. Nouri doesn't prescribe or sell medication.

← Back to all articles